Main Conference Day 3Wednesday, 17 December 2025 - PT (Pacific Time, GMT-08:00)

Since the first ADC approval 25 years ago, the MMAE vedotin platform has been the most widely utilized. Over 50 targets have been paired as vedotin ADCs and tested across heme and solid tumors, offering a rare opportunity to leverage insights about ADC target selection. Recent vedotin ADC NSCLC clinical data suggest that targets with unique biology, such as PD-L1 and Integrin Beta-6, are enabling success in a tumor type where other vedotin ADCs have failed.

This talk will share updates from the AIntibody competition, a benchmarking initiative engaging the biotech, pharma, academia, and AI communities to use AI and other informatic methods to design or identify developable antibodies with high affinities, from curated NGS datasets. Results will compare the properties of these antibodies with those derived using experimental methods, providing insights into the value of AI in antibody discovery. AIntibody announcement manuscript: Erasmus, M. F. et al. Nat Biotechnol 42, 1637-1642 (2024).